Skip to content
Business Times – Lifestyle
Author:
Cellectis Inc.
Cellectis to Report Second Quarter Financial Results on August 6, 2026
July 30, 2026
Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026
June 25, 2026
Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress
June 11, 2026
Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL
June 9, 2026
Cellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026
May 20, 2026
Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress
May 12, 2026
Cellectis Reports Financial Results for the First Quarter 2026
May 11, 2026
Cellectis to Report First Quarter Financial Results on May 11, 2026
May 4, 2026
Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting
April 29, 2026
Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform
April 13, 2026
1
2
Next Page
→